Eledon Pharmaceuticals, Inc. reported a net loss of $17.5 million for the third quarter of 2025, a significant decline from a net income of $77.0 million in the same period last year. The company's total operating expenses for the quarter were $19.1 million, down from $20.5 million in the prior year, primarily due to reduced research and development costs. For the nine months ending September 30, 2025, Eledon recorded a net loss of $35.2 million, compared to a net income of $8.4 million for the same period in 2024. The substantial shift in profitability is attributed to a decrease in the fair value of warrant liabilities, which fell by $22.9 million in 2025, compared to a $51.8 million decrease in the previous year.
Eledon's financial position has also changed significantly, with total assets decreasing to $129.9 million as of September 30, 2025, down from $177.4 million at the end of 2024. Cash and cash equivalents have dwindled to $3.7 million, a sharp decline from $20.5 million at the end of the previous fiscal year. The company’s accumulated deficit has increased to $390.8 million, reflecting ongoing investments in research and development without generating revenue from product sales. Eledon has indicated that it will need to raise additional funds to continue its operations, particularly for the clinical development of its lead compound, tegoprubart.
Strategically, Eledon has focused its resources on the development of tegoprubart, an anti-CD40L antibody aimed at preventing organ rejection in kidney transplants and treating amyotrophic lateral sclerosis (ALS). The company has made significant progress in its clinical trials, including a Phase 1b study for kidney transplantation, where interim results have shown promising kidney function outcomes. However, Eledon has deprioritized its IgA nephropathy program and is seeking additional financing to support its ALS development efforts.
Operationally, Eledon has seen a decrease in research and development expenses, which totaled $14.9 million for the third quarter of 2025, down from $16.5 million in the same quarter of 2024. This reduction is primarily due to lower external costs associated with clinical trials. The company has also increased its personnel-related expenses, reflecting a higher headcount to support ongoing clinical development. As of September 30, 2025, Eledon had approximately 77.2 million shares outstanding, with a basic net loss per share of $0.21 for the quarter.
Looking ahead, Eledon anticipates that its existing cash and short-term investments will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for additional financing to support its clinical programs and operational needs. Eledon is exploring various financing options, including public and private equity offerings, to ensure it can continue its development activities and achieve its strategic goals.
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals is a biotech company focused on developing immunology-based therapies targeting the CD40 Ligand pathway. Its lead candidate, tegoprubart, is an anti-CD40L antibody designed to prevent organ transplant rejection, treat autoimmune diseases, and address neurodegenerative conditions like ALS. The company advances its products through clinical trials, leveraging proprietary IP, and collaborates with research institutions to improve transplant outcomes and neuroinflammation management.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.